Tuesday 15th March 2022 |
Text too small? |
Pushpay reconfirms and narrows FY22 guidance range, and provides disclosure relating to the repurchase of unallocated employee share scheme shares
Pushpay Holdings Limited (NZSX:PPH, ASX:PPH, ‘Pushpay’ or ‘the Company’) advises that it has reconfirmed and narrowed its previous guidance for the year ending 31 March 2022, and now expects Underlying EBITDAFI[1] to be between US$61.5 million and US$63.5 million (previously Underlying EBITDAFI of between US$60.0 million and US$65.0 million). Excluding the costs associated with the investment into the Catholic initiative, Pushpay expects to achieve Underlying EBITDAFI for the year ending 31 March 2022 of between US$63.5 million and US$65.5 million. The Company’s guidance for the year ending 31 March 2022 represents an increase in Underlying EBITDAFI performance of between 6% to 10% when compared to the prior financial year ended 31 March 2021.
Pushpay continues to see positive year-on-year increases in processing volume performance in each trading month of the 2022 financial year, with the total processing volume for the eleven months ended 28 February 2022 being up 10% compared to the same period last year.
The Company’s strong operating cash flow continues to enable Pushpay to pay down its debt facility, which was obtained to partially fund the Resi Media acquisition in August 2021. Pushpay’s net debt balance has reduced from US$90.0 million as at August 2021, to US$54.0 million as at 28 February 2022. Pushpay looks forward to discussing the results for the year ending 31 March 2022 in more detail at the Company’s Annual Results announcement on Wednesday, 11 May 2022 (NZT).
Pushpay also advises that it is intending to buy back the remaining 138,336 Pushpay shares currently held by Pushpay Trustee Limited (Trustee) as trustee for a legacy employee share scheme. Further information is set out as attached. This requires no action from shareholders. A Disclosure Document will be sent to all shareholders today.
No comments yet
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report
RAD - Radius Care Announces On-market Share Buyback Programme
MCY - New wind farm propels MCY renewables commitment to $1b